by emma
30. September 2011 15:45
The FDA has approved Roche’s new generation of Accu-Chek Aviva Plus test strips to monitor blood glucose levels in diabetes patients.
The new self-monitoring strips are designed to prevent the interference of maltose on blood sugar readings which occurs rarely when a patient takes medication metabolising to maltose.
Daniel O’ Day, Chief Operating Officer at Roche Diagnostics, said: “With its advanced technology and chemistry it is designed to support patients to manage their condition more effectively.”
More than 25 million people live with diabetes in the US, of which seven million are currently undiagnosed.
Roche’s Accu-Chek portfolio manufactures blood glucose readers, insulin delivery systems and lancing devices.
3ccc9ad1-fe2c-4294-a2cd-a0815d4b6175|0|.0
Tags: FDA, USA, US, Roche, AccuNostics, Accu-Chek, Aviva plus, test strips, diagnostics, diagnose, diagnosis, monitoring, blood glucose levels, blood sugar levels, diabetes, patients, diabetic, maltose, medication, medicine, treatment, therapy, health, healthcare, patient care, self monitoring, Daniel O'Day, Chief operating officer, Roche Diagnostics, medical tech, medical technologies, med tech, medtech, insulin delivery, devices, medical devices, medtech device
Medtech News
Subscribe